2017 Q2 Form 10-Q Financial Statement
#000156459017016559 Filed on August 08, 2017
Income Statement
| Concept | 2017 Q2 | 2016 Q2 |
|---|---|---|
| Revenue | $30.48M | $97.00K |
| YoY Change | 31317.53% | 9600.0% |
| Cost Of Revenue | $2.224M | $526.0K |
| YoY Change | 322.81% | |
| Gross Profit | $28.25M | -$429.0K |
| YoY Change | -6685.31% | |
| Gross Profit Margin | 92.7% | -442.27% |
| Selling, General & Admin | $61.10M | $50.77M |
| YoY Change | 20.35% | 140.61% |
| % of Gross Profit | 216.28% | |
| Research & Development | $34.20M | $20.48M |
| YoY Change | 67.01% | 11.42% |
| % of Gross Profit | 121.06% | |
| Depreciation & Amortization | $680.0K | $450.0K |
| YoY Change | 51.11% | 60.71% |
| % of Gross Profit | 2.41% | |
| Operating Expenses | $95.30M | $71.25M |
| YoY Change | 33.76% | 80.38% |
| Operating Profit | -$68.43M | -$71.92M |
| YoY Change | -4.85% | 82.1% |
| Interest Expense | $993.0K | $601.0K |
| YoY Change | 65.22% | 405.04% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $0.00 | |
| YoY Change | ||
| Pretax Income | -$67.04M | -$71.30M |
| YoY Change | -5.97% | 80.96% |
| Income Tax | $398.0K | |
| % Of Pretax Income | ||
| Net Earnings | -$67.44M | -$71.32M |
| YoY Change | -5.44% | 81.12% |
| Net Earnings / Revenue | -221.3% | -73527.84% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$552.0K | -$629.3K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 113.2M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q2 | 2016 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $417.3M | $412.6M |
| YoY Change | 1.14% | 52.38% |
| Cash & Equivalents | $143.8M | $131.8M |
| Short-Term Investments | $273.5M | $280.8M |
| Other Short-Term Assets | $8.000M | $6.800M |
| YoY Change | 17.65% | 518.18% |
| Inventory | $6.000M | $2.867M |
| Prepaid Expenses | ||
| Receivables | $11.60M | $300.0K |
| Other Receivables | $800.0K | $1.300M |
| Total Short-Term Assets | $443.7M | $423.9M |
| YoY Change | 4.67% | 55.05% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $3.300M | $2.897M |
| YoY Change | 13.91% | 59.79% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | $7.754M | |
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $3.000M | $1.111M |
| YoY Change | 170.03% | 233.63% |
| Total Long-Term Assets | $12.60M | $14.14M |
| YoY Change | -10.87% | 558.76% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $443.7M | $423.9M |
| Total Long-Term Assets | $12.60M | $14.14M |
| Total Assets | $456.3M | $438.0M |
| YoY Change | 4.17% | 58.97% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.600M | $1.024M |
| YoY Change | 251.56% | -64.88% |
| Accrued Expenses | $37.30M | $27.49M |
| YoY Change | 35.71% | 66.96% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $40.90M | $29.02M |
| YoY Change | 40.93% | 49.77% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $300.0K | $200.0K |
| YoY Change | 50.0% | -33.33% |
| Total Long-Term Liabilities | $300.0K | $197.0K |
| YoY Change | 52.28% | -42.06% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $40.90M | $29.02M |
| Total Long-Term Liabilities | $300.0K | $197.0K |
| Total Liabilities | $41.20M | $29.22M |
| YoY Change | 41.0% | 48.18% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$783.7M | |
| YoY Change | 35.61% | |
| Common Stock | $11.00K | |
| YoY Change | 10.0% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $415.1M | $408.8M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $456.3M | $438.0M |
| YoY Change | 4.17% | 58.97% |
Cashflow Statement
| Concept | 2017 Q2 | 2016 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$67.44M | -$71.32M |
| YoY Change | -5.44% | 81.12% |
| Depreciation, Depletion And Amortization | $680.0K | $450.0K |
| YoY Change | 51.11% | 60.71% |
| Cash From Operating Activities | -$58.80M | -$56.75M |
| YoY Change | 3.61% | 89.99% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$260.0K | -$8.580M |
| YoY Change | -96.97% | 1180.6% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $38.56M | $1.120M |
| YoY Change | 3342.86% | -97.5% |
| Cash From Investing Activities | $38.29M | -$7.460M |
| YoY Change | -613.27% | -116.93% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 7.010M | 20.76M |
| YoY Change | -66.23% | 698.46% |
| NET CHANGE | ||
| Cash From Operating Activities | -58.80M | -56.75M |
| Cash From Investing Activities | 38.29M | -7.460M |
| Cash From Financing Activities | 7.010M | 20.76M |
| Net Change In Cash | -13.50M | -43.45M |
| YoY Change | -68.93% | -358.63% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$58.80M | -$56.75M |
| Capital Expenditures | -$260.0K | -$8.580M |
| Free Cash Flow | -$58.54M | -$48.17M |
| YoY Change | 21.53% | 64.97% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-129561000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-19831000 | ||
| us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
43000 | ||
| us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
99000 | ||
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-4000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1927000 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
112327000 | ||
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-263000 | ||
| us-gaap |
Depreciation
Depreciation
|
342000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
5691000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
|
-453000 | ||
| CY2017Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-67632000 | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
33815000 | ||
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
297000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2512000 | ||
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
738000 | ||
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
782000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-324000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-648000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
1253000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
7001000 | ||
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
105000 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
196000 | ||
| CY2016Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
1000 | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
293000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
|
-298000 | ||
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-35000 | ||
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
326629000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
749000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
341990000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
25838000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
289429000 | ||
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
246000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-155487000 | ||
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
223000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
787000 | ||
| us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
254000 | ||
| us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
97000 | ||
| us-gaap |
License Costs
LicenseCosts
|
248000 | ||
| CY2016Q2 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
526000 | |
| CY2017Q2 | us-gaap |
Revenues
Revenues
|
30475000 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1452272000 | |
| us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
45761000 | ||
| CY2017Q2 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
2224000 | |
| us-gaap |
Other Sales Revenue Net
OtherSalesRevenueNet
|
4000 | ||
| CY2016Q2 | us-gaap |
Revenues
Revenues
|
97000 | |
| us-gaap |
Revenues
Revenues
|
45761000 | ||
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
203001000 | ||
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
122286000 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-199000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
69589000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-157240000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-122185000 | ||
| CY2016Q2 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
601000 | |
| CY2017Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-3000 | |
| CY2017Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
122122000 | |
| CY2016Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-71322000 | |
| us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
127268000 | ||
| us-gaap |
Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
|
2000000 | ||
| us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
78259000 | ||
| CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-68434000 | |
| CY2016Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-71923000 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
43253000 | ||
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
1956000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-2644000 | ||
| CY2016Q2 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
50768000 | |
| CY2017Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
98909000 | |
| CY2016Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
72020000 | |
| CY2017Q2 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
993000 | |
| us-gaap |
Depreciation
Depreciation
|
577000 | ||
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
1101000 | ||
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-1000 | ||
| CY2017Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.55 | |
| us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
-5000 | ||
| CY2016Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
113308000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-155284000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-121084000 | ||
| CY2016Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.63 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.27 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.08 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
121888000 | ||
| CY2017Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-188000 | |
| CY2016Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-111000 | |
| CY2016Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-71432000 | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-120889000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
498000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
4623000 | ||
| us-gaap |
Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
|
100000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
159260000 | ||
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
250007000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-176156000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
513000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-97957000 | ||
| us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
8000000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
91234000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
18500000 | ||
| us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
14320000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
18500000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
303749000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-4000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
29636000 | ||
| CY2016Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
131774000 | |
| us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
355000 | ||
| CY2016Q4 | acad |
Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
|
1999000 | |
| CY2016Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1609000 | |
| CY2016Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
1820000 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
14404000 | ||
| CY2016Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
13883000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
33815000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
25838000 | ||
| CY2016Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
2355000 | |
| CY2016Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
9488000 | |
| CY2016Q4 | acad |
Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
|
8551000 | |
| CY2016Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
281600000 | |
| CY2016Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
10344827 | |
| CY2017Q2 | us-gaap |
Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
|
3600000 | |
| us-gaap |
Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
|
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. Recent Accounting Pronouncements</p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-18, <font style="font-style:italic;">Statement of Cash Flows: Restricted Cash</font>, which requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included within cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating when it will adopt this guidance. The adoption of this ASU will modify the Company’s current classification within the consolidated statement of cash flows but is not expected to materially impact the Company’s consolidated financial statements.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016,<font style="color:#000000;"> the FASB issued ASU 2016-13, </font><font style="font-style:italic;color:#000000;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</font><font style="color:#000000;">, which changes the impairment model for most financial assets and certain other instruments. For trade receivables and other instruments, entities will be required to use a new forward-looking expected loss model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. This guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those years, with early adoption permitted only as of annual reporting periods beginning after December 15, 2018. The Company is currently evaluating the timing and impact of the adoption of this guidance on the Company’s consolidated financial statements</font>.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <font style="color:#000000;">March 2016, the FASB issued ASU 2016-09, </font><font style="font-style:italic;color:#000000;">Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting</font><font style="color:#000000;">, which is intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows, and accounting for forfeitures. This guidance was effective for annual reporting periods beginning after December 15, 2016, including interim periods within those years. The Company adopted this guidance in the first quarter of 2017 using the modified retrospective transition method. Accordingly, the Company increased its deferred tax assets by $36.8 million, with a corresponding increase to its valuation allowance, to record previously unrecognized excess tax benefits. Additionally, the Company elected to make an accounting policy change to recognize forfeitures as they occur. As a result, the Company recorded an increase to additional paid-in capital and a corresponding increase to accumulated deficit of $0.3 million, respectively, to reflect the incremental stock-based compensation expense that would have been recognized in prior years pursuant to the modified guidance. Additionally, the Company increased its deferred tax assets by $0.1 million, with a corresponding increase to its valuation allowance, to record the excess tax benefit from the change</font>.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, <font style="color:#000000;">the FASB issued ASU 2016-02, </font><font style="font-style:italic;color:#000000;">Leases</font><font style="color:#000000;">, which requires a lessee to recognize a lease liability and a right-of-use asset for all leases with lease terms of more than 12 months. This guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those years, and early adoption is permitted. Companies are required to adopt this guidance using a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. While the Company is still evaluating the timing and impact of the adoption of this guidance on its consolidated financial statements, it anticipates that the adoption could result in an increase in the assets and liabilities recorded on its consolidated balance sheet.</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <font style="color:#000000;">May 2014, the FASB issued ASU 2014-09, </font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers</font><font style="color:#000000;">, which supersedes nearly all existing revenue recognition guidance under generally accepted accounting principles. This ASU, as amended, is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. The original guidance was effective for annual reporting periods beginning after December 15, 2016. However, in July 2015, the FASB agreed to delay the effective date by one year, with early adoption permitted, but not before the original effective date of the standard. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company anticipates adopting ASU 2014-09 on January 1, 2018. The Company’s evaluation of the guidance is ongoing, including the assessment of the adoption method, the evaluation of the Company’s contracts with its customers, and the evaluation of information necessary to restate prior period financial statements. At present, the Company has one source of revenue: the sale of NUPLAZID to its customers. The Company’s evaluation of the customer contracts governing these sales is still underway. However, recognition of the Company’s revenue under the new standard is expected to be materially consistent with the Company’s current revenue recognition policy, which uses the sell-in method. The new standard is not expected to materially impact the timing or amounts of revenue recognized</font>.</p></div> | ||
| us-gaap |
Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
|
0 | ||
| us-gaap |
Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
|
0 | ||
| CY2016Q2 | acad |
Regulatory Milestone Payment
RegulatoryMilestonePayment
|
8000000 | |
| CY2016Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
8000000 | |
| CY2017Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
400000 | |
| CY2017Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
700000 | |
| CY2017Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
1500000 | |
| CY2017Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
1500000 | |
| CY2017Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
1500000 | |
| CY2017Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
1000000 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
16563000 | ||
| CY2017Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
18244000 | |
| CY2017Q2 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
4088000 | |
| CY2017Q2 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
1915000 | |
| CY2017Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
11072000 | |
| CY2016Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
14382000 | |
| CY2017Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
9767000 | |
| CY2017Q2 | acad |
Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
|
6077000 | |
| CY2017Q2 | acad |
Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
|
5792000 | |
| CY2017Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
4617000 | |
| CY2017Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
273638000 | |
| CY2017Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
2000 | |
| CY2017Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
109000 | |
| CY2016Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
365324000 | |
| CY2016Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
172000 | |
| CY2016Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
80000 | |
| CY2017Q2 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
414239000 | |
| CY2016Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
523433000 | |
| CY2016Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
215900000 | |
| CY2016Q3 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
6969696 | |
| acad |
Number Of Sources Of Revenues
NumberOfSourcesOfRevenues
|
1 |
